Evolution of direct costs in the first years of rheumatoid arthritis: Impact of early versus late biologic initiation - An economic analysis based on the ESPOIR cohort

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Chevreul, Karine ^a,b,c   Haour, Georges ^a   Lucier, Sandy ^a   Harvard, Stephanie ^a,d   Laroche, Marie Laure ^e,f   Mariette, Xavier ^g   Saraux, Alain ^h   Durand Zaleski, Isabelle ^a,b,c,j   Guillemin, Francis ⁱ   Fautrel, Bruno ^d,k  

^a HÔTEL DIEU   (France)

^b Paris Diderot University   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE LIMOGES   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

ⁱ UNIVERSITÉ DE LORRAINE   (France)

^j HENRI MONDOR HOSPITAL   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; PREDNISONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DRUG COST; FEMALE; FIRST YEAR BIOLOGIC INITIATION; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HUMAN; LATER YEAR BIOLOGIC INITIATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; CLINICAL TRIAL; COHORT ANALYSIS; COST; ECONOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME;

ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME FACTORS;

EID: 84901499168     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097077     Document Type: Article

References (42)

1. Alamanos Y, Drosos AA (2005) Epidemiology of rheumatoid arthritis. Autoimmun Rev 4: 130-36.
2. Uhlig T, Kvien T (2005) Is rheumatoid arthritis disappearing? Ann Rheum Dis 64: 7-10. (Pubitemid 40075266)
3. st 2013.
4. Guillemin F, Durieux S, Daurès JP, Lafuma A, Saraux A et al. (2004) Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists. J Rheumatol 31: 1297-304. (Pubitemid 38879192)
5. Kobelt G, Woronoff AS, Richard B, Peeters P, Sany J (2008) Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine 75: 408-15.
6. Wolfe F, Michaud K (2010) The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 12: R35.
7. Lundkvist J, Kastang F, Kobelt G (2008) The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ (Suppl 2): S49-60.
8. Fautrel B, Verstappen SM, Boonen A (2011) Economic consequences and potential benefits. Best Pract Res Clin Rheumatol 25: 607-24.
9. Rosery H, Bergemann R, Maxion-Bergemann S (2005) International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics 23: 243-57. (Pubitemid 40663631)
10. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59: 762-84. (Pubitemid 351847559)
11. Finckh A, Bansback N, Marra CA, Anis AH, Michaud K et al. (2009) Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 151: 612-21.
12. Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F (2011) Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature. Int J Rheumatol Doi:10.1155/2011/ 845496.
13. Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL (2009) Cost-ofillness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 27: S118-23.
14. Combe B, Benessiano J, Brenbaum F, Cantagrel A, Daurès JP et al. (2007) The ESPOIR cohort: A ten-year follow-up of early arthritis in France: Methodology and baseline characteristics of the 813 included patients. Joint Bone Spline 74: 440-5. (Pubitemid 47588984)
15. st 2013.
16. OECD Health Data (2007) ECOSANTE [database on the Internet]. Available: http://ecosante.fr/. Accessed June 1st 2013.
17. Chevreul K, Prigent A, Bourmaud A, Leboyer M, Durand-Zaleski I (2012) The cost of mental disorders in France. Eur Neuropsychopharmacol Doi: 10.1016/j.euroneuro.2012.08.012.
18. st 2013.
19. st 2013.
20. st 2007.
21. st 2013.
22. Grieve R, Nixon R, Thompson SG, Normand C (2005) Using multilevel models for assessing the variability of multinational resource use and cost data. Health Econ 14: 185-96. (Pubitemid 40253633)
23. Raudenbush SW, Bryk AS (2001) Hierarchical Linear Models: Applications and Data Analysis Methods. Second Edition. Newbury Park, CA: SAGE. 79 p.
24. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23: 137-45. (Pubitemid 10164318)
25. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6): 964-75.
26. Allison PD (2005) Imputation of Categorical Variables with PROC MI. Proceedings of the Thirtieth Annual SAS Users Group International (SUGI) Conference; 2005. Cary, North Carolina: SAS Institute Inc.
27. Graham JW (2009) Missing Data Analysis: Making It Work in the Real World. Annu Rev Psychol 60: 549-76.
28. Collins LM, Schafer JL, Kam C-M (2001) A comparison of inclusive and restrictive strategies in modern missing data procedures. Psychol Methods 6: 330-51. (Pubitemid 33599063)
29. Rubin DB (1987) Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons, Inc. 76 p.
30. Fautrel B, Combe B, Rincheval N, Dougados M, ESPOIR Scientific Commitee (2012) Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data. Ann Rheum Dis 71: 386-89.
31. Adami S, Bernardi D, Rossi E, Rossini M, De Rosa M (2013) Drug use and Cost Evaluation In Rheumatoid Arthritis Patients. Value Health16: A221.
32. Kawatkar AA, Jacobsen SJ, Levy GD, Medhekar SS, Venkatasubramaniam KV et al. (2012) Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure survey. Arthritis Care Res (Hoboken) 64: 1649-56.
33. Fautrel B, Verstappen SMM, Boonen A (2011) Economic consequences and potential benefits. Best Pract Res Clin Rheumatol 25: 607-24.
34. Hallert E, Husberg M, Skogh T (2011) 28-joint count disease activity score at 3 months after diagnosis of early rheumatoid arthritis is strongly associated with direct and indirect costs over the following 4 years: the Swedish TIRA project. Rheumatology 50: 1259-67.
35. Michaud K, Messer J, Choi HK, Wolf F (2003) Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 48: 2750-62. (Pubitemid 37280602)
36. Zhu TY, Tam L-S, Li EK (2011) Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study. Rheumatology 50: 1293-1301.
37. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F et al. (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66: 34-45. (Pubitemid 46044858)
38. Knevel R, Schoels M, Huizinga TWJ, Aletaha D, Burmester GR et al. (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69: 987-994.
39. Rubin DC, Baddeley AD (1989) Telescoping is not time compression: a model of the dating of autobiographical events. Mem Cognit 17: 653-61. (Pubitemid 19268084)
40. Schafer JL, Graham JW (2002) Missing data: our view of the state of the art. Psychol Methods 7: 147-77.
41. von Hippel PT (2013) Should a Normal Imputation Model be modified to Impute Skewed Variables? Sociol Methods Res 42: 105-38.
42. Finckh A, Bansback N, Liang MH, Boers M (2010) Cost-effectiveness of biologics in early rheumatoid arthritis. Ann Intern Med 152: 333-4.